Bupropion in the Treatment of Postural Orthostatic Tachycardia Syndrome (Pots): A Single-Center Experience
Autor: | Blair P. Grubb, Rohit Vyas, Mohammed Ruzieh, Mohammad Al-Sarie, Zeid Nesheiwat, Zaid Ammari |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male 030213 general clinical medicine 030204 cardiovascular system & hematology Single Center Syncope General Biochemistry Genetics and Molecular Biology Norepinephrine (medication) Postural Orthostatic Tachycardia Syndrome 03 medical and health sciences Orthostatic vital signs 0302 clinical medicine mental disorders Humans Medicine Bupropion Retrospective Studies business.industry Gold standard technology industry and agriculture food and beverages Dopamine reuptake inhibitor General Medicine humanities Treatment Outcome Anesthesia Cardiovascular agent Orthostatic Intolerance Female Symptom Assessment business medicine.drug |
Zdroj: | Journal of Investigative Medicine. 68:1156-1158 |
ISSN: | 1708-8267 1081-5589 |
Popis: | Postural orthostatic tachycardia syndrome (POTS) is estimated to impact millions of people each year. However, there is no established gold standard for its treatment. Bupropion is a norepinephrine and a dopamine reuptake inhibitor and has been implicated as a potential treatment for POTS. We performed a non-randomized retrospective chart review on 47 patients with POTS with statistical analysis evaluating for significant findings including reduced orthostasis and improvement of symptoms with the use of bupropion. Bupropion was not associated with a statistically significant improvement in orthostatic vitals but there was an overall reduction in reported syncope. While the use of bupropion does not show a statistically significant impact on orthostatic vitals in patients with POTS, it did show a degree of improvement in syncope and as such might be useful in patients with syncope-predominant POTS. |
Databáze: | OpenAIRE |
Externí odkaz: |